分支型胸主动脉腔内修复术急诊治疗主动脉弓病变的初步经验
本研究回顾性分析了11例接受急诊分支型胸主动脉腔内修复术(b-TEVAR)的主动脉弓病变患者,技术成功率100%,30天死亡率为9%,早期再干预率为45%。随访中位6个月,2例存在持续假腔灌注,但所有主动脉上分支保持通畅。结果表明急诊b-TEVAR可行且安全,但早期再干预率不容忽视。
要点
- 急诊b-TEVAR技术成功率100%,30天死亡率9%。
- 早期再干预率45%,围术期并发症包括卒中、脓毒症等。
- 中位随访6个月,所有主动脉上分支通畅,2例假腔持续灌注。
核心结论
- 急诊b-TEVAR治疗主动脉弓病变可行且安全,但早期再干预率较高。
研究设计与样本
- 回顾性研究,纳入2012年12月至2017年12月单中心11例急诊b-TEVAR患者(5例男性,年龄67±14岁)。
主要发现
- 技术成功率为100%(11/11)。
- 30天死亡率为9%(1/11)。
- 围术期并发症包括重大卒中1例(9%)、脓毒症1例(9%)、呼吸衰竭2例(18%)、急性肾损伤1例(9%)和腹膜后血肿1例(9%)。
- 早期再干预5例(45%)。
- 中位随访6个月(范围1-28个月),2例存在持续假腔灌注,所有主动脉上分支保持通畅。
临床怎么用
- 在急诊情况下,b-TEVAR可作为主动脉弓病变的治疗选择,但需警惕早期再干预风险。
- 支架移植物可从其他相似解剖患者借用,实现急诊使用。
局限性
- 样本量小(11例),为单中心回顾性研究。
- 随访时间较短(中位6个月)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Branched thoracic endovascular aortic repair (b-TEVAR) has revolutionized the treatment of aortic arch pathologies. However, b-TEVAR requires custom design and time for manufacturing, which limits its use in emergency situation. METHODS: We retrospectively studied a series of 11 patients, who underwent emergency b-TEVAR in our institution. Stent grafts were either already available for the patient or from another patient with similar anatomy. Study endpoints were technical success, 30-day mortality, perioperative complications, early reinterventions, and subsequent image follow-up. RESULTS: Between December 2012 and December 2017, 11 patients (5 male; age 67 ± 14 years) were treated emergently with b-TEVAR for type A dissection (n = 2), peripheral malperfusion despite ascending repair in type A dissection (n = 1), contained ruptured ascending aortic pseudoaneurysm (n = 2), symptomatic arch aneurysm (n = 4), and ruptured subclavian aneurysm (n = 2). Three patients received their personal custom-made endografts but were hospitalized and treated urgently because of new symptom onset; the remaining 8 patients were treated with endografts from other patients. Technical success was 100%. Thirty-day mortality was 9% (1 of 11). Perioperative complications included one major stroke (9%), one sepsis (9%), two respiratory failures (18%), one acute renal injury (9%), and one retroperitoneal hematoma (9%). There were five (45%) early reinterventions. With median 6 months (range, 1 to 28) of follow-up, 2 patients had persistent false lumen perfusion, whereas all supraaortic branches remained patent. CONCLUSIONS: Our experience provided an early insight to the feasibility and safety of b-TEVAR in an emergency situation, although the early reintervention rate was not negligible. The endograft was versatile, with potential off-the-shelf use in future.
引用
- Law Y, Kölbel T, Detter C, et al. Emergency Use of Branched Thoracic Endovascular Repair in the Treatment of Aortic Arch Pathologies. Ann Thorac Surg. 2018. PMID: 30389447. doi:10.1016/j.athoracsur.2018.09.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。